What is PhoreMost?
PhoreMost, established in 2014 and headquartered in Cambridge, United Kingdom, is at the forefront of developing a next-generation phenotypic screening platform. This innovative technology aims to revolutionize drug discovery and development by providing a more comprehensive and predictive approach to identifying potential therapeutic candidates. The company's platform is designed to accelerate the research process, enabling scientists to gain deeper insights into disease mechanisms and drug efficacy.
How much funding has PhoreMost raised?
PhoreMost has raised a total of $68.8M across 3 funding rounds:
Angel/Seed
$3.8M
Series A
$15M
Series B
$50M
Angel/Seed (2015): $3.8M with participation from Cambridge Enterprise
Series A (2018): $15M, investors not publicly disclosed
Series B (2024): $50M supported by Jonathan Milner, Parkwalk Advisors, XtalPi, Trend Investments Group, Astellas Venture Management, BGF, o2h ventures, and The Morningside Group
Key Investors in PhoreMost
Parkwalk Advisors
Parkwalk Advisors is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. With over 15 years of experience, they bridge the gap between academic research and commercial success by providing funding, expertise, and networks to help these companies thrive. Their investment strategy spans the entire spinout lifecycle, supporting ventures in sectors such as AI, Quantum Computing, HealthTech, and CleanTech. Parkwalk offers tax-efficient investment opportunities for those looking to support groundbreaking science and technology.
Astellas Venture Management
Astellas Pharma is engaged in the manufacturing, marketing, import, and export of pharmaceuticals. It is headquartered in Tokyo, Japan.
BGF
BGF, headquartered in London, United Kingdom, is the most active and influential investor in small and mid-sized businesses in the UK. An established and independent company, it supports a range of growing companies - early stage, growth stage, and quoted - across every region and sector of the economy.
What's next for PhoreMost?
The recent major strategic investment signals a pivotal phase for PhoreMost, likely enabling the company to scale its operations, enhance its proprietary screening platform, and potentially expand its market reach. This infusion of capital is expected to fuel further research and development, foster strategic partnerships, and accelerate the commercialization of its technology. The company's focus on advanced phenotypic screening positions it to address critical challenges in the pharmaceutical and biotechnology industries, driving innovation in therapeutic development.
See full PhoreMost company page
